Suchergebnisse - "Ziepert, Marita"

PubPharm (16)

1

KIR2DS1-HLA-C status as a predictive marker for benefit from rituximab : a post-hoc analysis of the RICOVER-60 and CLL8 trials

enthalten in: The Lancet. Haematology | 2022

von Kaddu-Mulindwa, D. | Altmann, B. | Robrecht, S. | +19

CommentIn: Lancet Haematol. 2022 Feb;9(2):e88-e89. - PMID 35114157

2

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

enthalten in: Blood | 2021

von Schmitz, N. | Truemper, L. | Bouabdallah, K. | +38

CommentIn: Blood. 2021 May 13;137(19):2570-2571. - PMID 33983423

3

Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma : 10-year follow-up of a randomised, open-label, phase 3 trial

enthalten in: The Lancet. Haematology | 2021

von Frontzek, F. | Ziepert, M. | Nickelsen, M. | +18

CommentIn: Lancet Haematol. 2021 Apr;8(4):e242-e243. - PMID 33667421

4

Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma : the DSHNHL2006-1B/ACT-2 trial

enthalten in: Leukemia | 2021

von Wulf, G. | Altmann, B. | Ziepert, M. | +26

5

Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER) : a randomised, phase 3, non-inferiority trial

enthalten in: Lancet (London, England) | 2019

von Poeschel, V. | Held, G. | Ziepert, M. | +43

CommentIn: Lancet. 2020 Dec 21;394(10216):2208-2209. - PMID 31868615

6

The impact of SOCS1 mutations in diffuse large B-cell lymphoma

enthalten in: British journal of haematology | 2019

von Mellert, K. | Martin, M. | Lennerz, J. | +15

7

Optimization of rituximab for the treatment of DLBCL : increasing the dose for elderly male patients

enthalten in: British journal of haematology | 2017

von Pfreundschuh, M. | Murawski, N. | Zeynalova, S. | +16

8

Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2017

von Staiger, A. | Ziepert, M. | Horn, H. | +21

9

Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2014

von Bittenbring, J. | Neumann, F. | Altmann, B. | +7

10

The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial aggressive B-cell lymphomas

enthalten in: Blood | 2014

von Murawski, N. | Held, G. | Ziepert, M. | +12